CN112961091B - Amino lipide compound and preparation method and application thereof - Google Patents
Amino lipide compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN112961091B CN112961091B CN202110178738.7A CN202110178738A CN112961091B CN 112961091 B CN112961091 B CN 112961091B CN 202110178738 A CN202110178738 A CN 202110178738A CN 112961091 B CN112961091 B CN 112961091B
- Authority
- CN
- China
- Prior art keywords
- compound
- amino
- alkyl
- lipid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
The invention relates to an amino lipide compound, a compound shown in a chemical formula I, or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof,
also disclosed are methods for the preparation of the compounds and their use as components for the delivery of therapeutic agents and in the preparation of medicaments.
Description
Technical Field
The invention relates to an amino lipid compound, in particular to an amino lipid compound which can be used for delivering genes into cells, and a preparation method and application thereof.
Background
Gene therapy is the artificial delivery of genes with specific genetic information to target cells, and the expressed target proteins have the effects of regulating, treating and even curing diseases caused by congenital or acquired gene defects. Both nucleic acid and cell membrane have negative charge, so that naked nucleic acid is difficult to directly introduce into cell, and is easily degraded by nucleic acid degrading enzyme in cytoplasm, and can not reach the action of gene introduction and gene therapy, so that it can implement gene transfer by means of external force or carrier. Genetic vectors are generally classified into viral vectors and non-viral vectors. The viral vector has extremely high transfection efficiency in vivo and in vitro, but has a plurality of defects such as high toxicity, strong immune response, small gene capacity, poor targeting property, complex preparation process and the like. Non-viral vectors have gained increasing attention and application due to their ease of preparation, transport, and storage, safety, efficacy, lack of immunogenicity, and the like.
However, gene delivery currently faces two problems during therapy relative to gene delivery at the cellular level. First, free RNA is susceptible to nuclease digestion in plasma. A frequently used solution is to introduce into the nanoparticles phosphonate ester loaded with PEG chains, which extend at the outermost layer of the micelle during self-assembly. Because the PEG layer has the characteristics of electric neutrality, protein adsorption resistance, no functional group at the end group and the like, the PEG layer can reduce the cytotoxicity of the nano carrier in vivo and prolong the cycle time. Second, after endocytosis of the cell, the gene vector can be transported into endosomal/lysosomal vesicles, where the gene is readily degraded by enzymes or acidic materials that are abundant in the lysosome. Therefore, the ability of nucleic acids to escape from endosomes/lysosomes into the cytoplasm is an important link for gene delivery in non-viral vectors. In the endosomal/lysosomal pathway, the nanocomplex undergoes a process of acidity reduction from pH 5-6 in late endosomes to lysosomes at pH about 4.5, which are rich in lysosomal enzymes and highly susceptible to degradation of the nanocomplex, and commonly used non-viral vectors have very low efficiency of endosomal/lysosomal escape and inefficient gene delivery.
Disclosure of Invention
Aiming at the existing defects, the invention provides an amino lipid compound for delivering genes into cells, and a preparation method and application thereof.
The technical scheme adopted by the invention for solving the technical problems is as follows: an aminolipidic compound, a compound of formula I, or a stereoisomer, or a tautomer, or a pharmaceutically acceptable salt thereof:
wherein:
R1-R2independently of each other, selected from the following structures: the R is1Is one of N6, N7, N8, N9, N10, N11, N12, N13, N14, N15, N16, N18, N19, N20 selected from:
N6:CH3(CH2)5-；N7:CH3(CH2)6-；N8:CH3(CH2)7-；
N9:CH3(CH2)8-；N10：CH3(CH2)9-；N11:CH3(CH2)10-；
N12:CH3(CH2)11-；N13:CH3(CH2)12-；N14:CH3(CH2)13-；
N15:CH3(CH2)14-；N16:CH3(CH2)15-；N18:CH3(CH2)17-；
N19:
N20:
the R is2Is one selected from a6, a7, A8, a9, a10, a11, a12, a13, a14, a15, a16, a18, a19, a 20:
A6:CH3(CH2)4-；A7:CH3(CH2)5-；A8:CH3(CH2)6-；
A9:CH3(CH2)7-；A10：CH3(CH2)8-；A11:CH3(CH2)9-；
A12:CH3(CH2)10-；A13:CH3(CH2)11-；A14：CH3(CH2)12-；
A15:CH3(CH2)13-；A16:CH3(CH2)14-；A18:CH3(CH2)16-；
A19
A20:
-X-L-N(R3)(R4) Is any one of O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10 selected from the following:
O1：
O2：
O3：
O4：
O5：
O6：
O7：
O8：
O9：
O10：
D1：
D2：
D3：
D4：
D5：
D6：
D7：
D8：
D9：
D10：
n is 1 or 2.
A method for preparing amino lipid compound comprises the following steps:
s1, reacting compound NH2-R1And R2-CHO reacting in solvent under stirring, distilling to remove solvent, adding cyclic acid anhydride, heating to react, purifying to obtain compound (II) with structural formula as follows,
s2, reacting the compound (II) with
The alcohol or amine is reacted in the presence of a condensing agent to obtain the compound (I), the structural formula is as follows,
wherein:
R1-R2independently of each other, selected from the following structures: the R is1Is one of N6, N12, N13, N16, N19, N20 selected from:
N6:CH3(CH2)5-；N12:CH3(CH2)11-；N13:CH3(CH2)12-；N16:CH3(CH2)15-；
N19:
N20:
the R is2Is one selected from a9, a10, a12, a13, a16, a18, a19, a 20:
A9:CH3(CH2)7-；A10：CH3(CH2)8-；A12:CH3(CH2)10-；A13:CH3(CH2)11-；
A16:CH3(CH2)14-；A18:CH3(CH2)16-；
A19:
A20:
-X-L-N(R3)(R4) Is any one of O1, O2, O5, O6, O8, O9, O10, D1, D4, D5 and D6 which are selected from the following components:
O1：
O2：
O5：
O6：
O8：
O9：
O10：
D1：
D4：
D5：
D6：
n is 1 or 2.
Use of an aminolipidic compound as a medicament for any of the nucleic acid transfer of any of the foregoing compounds, wherein when n ═ 1, X is not O as a medicament for nucleic acid transfer
Preferably, the nucleic acid is any one of RNA, mRNA, antisense oligonucleotide, DNA, plasmid, rRNA, miRNA, tRNA, siRNA, and snRNA.
"substituted" as referred to above is optional, i.e. one or more hydrogen atoms attached to the atom or group are independently unsubstituted or substituted with one or more substituents independently selected from: deuterium (D), halogen, -OH, mercapto, cyano, -CD3、C1-C6Alkyl (preferably C)1-C3Alkyl group), C2-C6An alkenyl group,C2-C6Alkynyl, cycloalkyl (preferably C)3-C8Cycloalkyl), aryl, heterocyclyl (preferably 3-8 membered heterocyclyl), heteroaryl, aryl C1-C6Alkyl-, heteroaryl C1-C6Alkyl radical, C1-C6Haloalkyl, -OC1-C6Alkyl (preferably-OC)1-C3Alkyl), -OC2-C6Alkenyl, OC1-C6Alkyl phenyl, C1-C6alkyl-OH (preferably C)1-C4alkyl-OH), C1-C6alkyl-SH, C1-C6alkyl-O-C1-C6Alkyl, OC1-C6Haloalkyl, NH2、C1-C6alkyl-NH2(preferably C)1-C3alkyl-NH2)、-N(C1-C6Alkyl radical)2(preferably-N (C)1-C3Alkyl radical)2)、-NH(C1-C6Alkyl) (preferably-NH (C)1-C3Alkyl)), -N (C)1-C6Alkyl) (C1-C6Alkylphenyl), -NH (C)1-C6Alkylphenyl), nitro, -C (O) -OH, -C (O) OC1-C6Alkyl (preferably-C (O) OC1-C3Alkyl), -CONRiri (Ri and Rii are H, D or C)1-C6Alkyl, preferably C1-C3Alkyl), -NHC (O) (C)1-C6Alkyl), -NHC (O) (phenyl), -N (C)1-C6Alkyl radical of C (O) (C)1-C6Alkyl), -N (C)1-C6Alkyl group C (O) (phenyl), -C (O) C1-C6Alkyl, -C (O) heteroaryl (preferably-C (O) -5-7 membered heteroaryl), -C (O) C1-C6Alkylphenyl, -C (O) C1-C6Haloalkyl, -OC (O) C1-C6Alkyl (preferably-OC (O) C)1-C3Alkyl), -S (O)2-C1-C6Alkyl, -S (O) -C1-C6Alkyl, -S (O)2-phenyl, -S (O)2-C1-C6Haloalkyl, -S (O)2NH2、-S(O)2NH(C1-C6Alkyl), -S (O)2NH (phenyl), -NHS (O)2(C1-C6Alkyl), -NHS (O)2(phenyl) and-NHS (O)2(C1-C6Haloalkyl), wherein each of the alkyl, cycloalkyl, phenyl, aryl, heterocyclyl, and heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of: halogen, -OH, -NH2Cycloalkyl, 3-8 membered heterocyclyl, C1-C4Alkyl radical, C1-C4Haloalkyl-, -OC1-C4Alkyl, -C1-C4alkyl-OH, -C1-C4alkyl-O-C1-C4Alkyl, -OC1-C4Haloalkyl, cyano, nitro, -C (O) -OH, -C (O) OC1-C6Alkyl, -CON (C)1-C6Alkyl radical)2、-CONH(C1-C6Alkyl), -CONH2、-NHC(O)(C1-C6Alkyl), -NH (C)1-C6Alkyl radical C (O) (C)1-C6Alkyl), -SO2(C1-C6Alkyl), -SO2(phenyl), -SO2(C1-C6Haloalkyl), -SO2NH2、-SO2NH(C1-C6Alkyl), -SO2NH (phenyl), -NHSO2(C1-C6Alkyl), -NHSO2(phenyl) and-NHSO2(C1-C6Haloalkyl). In this case, when one atom or group is substituted with a plurality of substituents, the plurality of substituents may be the same or different.
Wherein "alkyl" refers to the residue of aliphatic hydrocarbon after losing one hydrogen atom, and includes straight-chain or branched-chain, saturated or unsaturated alkyl, alkyl includes alkyl, alkenyl and alkynyl,
wherein "acyl" refers to hydrocarbyl-carbonyl, preferably said acyl is C4-C24An acyl group.
Wherein "alkoxy" means alkyl-oxy, preferably said alkoxy is C1-C10An alkoxy group.
Wherein "heterocycle" refers to a saturated or unsaturated cyclic group containing a heteroatom selected from N, O, S, which heterocycle may be optionally substituted with one or more substituents.
The invention has the beneficial effects that: the compound of the invention is an aminolipidic compound containing long apolar residues, the resulting compound all having hydrophobic character and, due to the amino group, also hydrophilic character, this amphoteric character can be used to form lipid particles, at the same time it has a 5-oxopyrrolidine-or 6-oxopiperidine group, the introduction of which significantly increases the membrane fusion to enhance the release of mRNA, thus promoting a synergistic improvement of mRNA delivery, being stable during the in vivo circulation, being rapidly degraded in endosomes/lysosomes, with significantly enhanced delivery efficiency. The preparation method of the amino lipid compound has the advantages of easily available raw materials, mild reaction conditions, good reaction selectivity, high reaction yield, low requirements on instruments and equipment and simple operation, and can be used as a medicament to remarkably improve the gene delivery efficiency.
Drawings
FIG. 1 is a body fluid antibody titer resulting from the delivery of OVA mRNA by subcutaneous administration of a representative amino lipid compound of an embodiment of the invention;
Detailed Description
To more clearly illustrate the objects, technical solutions and advantages of the embodiments of the present invention, the present invention will be further described in detail with reference to the accompanying drawings and embodiments, and it is obvious that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present invention without inventive step, are within the scope of the present invention.
Example 1: 1-dodecyl-5-oxo-2-undecylpyrrolidine-3-carboxylic acid
N-dodecylamine (1.85g,10mmol), n-dodecanal (1.84g,100mmol) and anhydrous methanol (100 mL) are sequentially added into a 250mL reaction flask, stirred at room temperature for reaction for 12 hours, the solvent is evaporated under reduced pressure, then xylene (150 mL) and succinic anhydride (1.00g,100mmol) are sequentially added, and the temperature is raised to 140 ℃ for reaction for 10 hours. After the solvent was evaporated to dryness under reduced pressure, 50mL of n-hexane was added, stirred, crystallized, filtered, washed with a small amount of n-hexane, and dried to give 1-dodecyl-5-oxo-2-undecylpyrrolidine-3-carboxylic acid (3.75g, 83%).
Example 2: synthesis of 1-hexadecyl-2-nonyl-6-oxopiperidine-3-carboxylic acid
Into a 250mL reaction flask were added n-hexadecylamine (2.42g,10mmol), n-decaldehyde (1.56g,100mmol) and anhydrous methanol (100 mL) in this order, and the mixture was stirred at room temperature for 12 hours, after the solvent was evaporated to dryness under reduced pressure, 150mL of xylene and glutaric anhydride (1.14g,100mmol) were added in this order, and the mixture was heated to 140 ℃ for 10 hours. After the solvent was evaporated to dryness under reduced pressure, 50mL of n-hexane was added, stirred, crystallized, filtered, washed with a small amount of n-hexane, and dried to obtain 1-hexadecyl-2-nonyl-6-oxopiperidine-3-carboxylic acid (3.51g, 71%).
Example 3: synthesis of ((Z) -octadecyl-9-en-1-yl) -5-oxo-2-undecylpyrrolidine-3-carboxylic acid
Oleylamine (2.68g,10mmol), n-decanal (1.56g,100mmol) and anhydrous methanol (100 mL) were added sequentially to a 250mL reaction flask, stirred at room temperature for 12 hours, the solvent was evaporated under reduced pressure, then xylene (150 mL) and succinic anhydride (1.00g,100mmol) were added sequentially, and the temperature was raised to 140 ℃ for reaction for 10 hours. After the solvent was evaporated under reduced pressure, 50mL of n-hexane was added, stirred, crystallized, filtered, washed with a small amount of n-hexane, and dried to give ((Z) -octadecyl-9-en-1-yl) -5-oxo-2-undecylpyrrolidine-3-carboxylic acid (4.54g, 85%).
Example 4: synthesis of 1-dodecyl-2- ((8Z, 11Z) -heptadecyl-8, 11-dien-1-yl) -5-oxopyrrolidine-3-carboxylic acid
N-dodecylamine (1.85g,10mmol), cis-9, 12-octadecadienal (2.64g,100mmol) and anhydrous methanol (100 mL) are sequentially added into a 250mL reaction flask, stirred at room temperature for reaction for 12 hours, after the solvent is evaporated to dryness under reduced pressure, xylene (150 mL) and succinic anhydride (1.00g,100mmol) are sequentially added, and the temperature is raised to 140 ℃ for reaction for 10 hours. After the solvent was evaporated to dryness under reduced pressure, 50mL of n-hexane was added, stirred, crystallized, filtered, washed with a small amount of n-hexane, and dried to give 1-dodecyl-2- ((8Z, 11Z) -heptadecyl-8, 11-dien-1-yl) -5-oxopyrrolidine-3-carboxylic acid (4.31g, 81%).
Example 5: synthesis of Compound N12A12C4O2
1-dodecyl-5-oxo-2-undecylpyrrolidine-3-carboxylic acid (903mg,2mmol), 3-dimethylamino-1-propanol (310mg,3mol), and 50mL of dichloromethane were sequentially added to a 250mL reaction flask, and after stirring and dissolving, dicyclohexylcarbodiimide (824mg,4mmol), 4-dimethylaminopyridine (5mg,0.04mmol) were added, and the mixture was reacted at room temperature for 2 hours, washed with water for 3 times, dried over anhydrous sodium sulfate, concentrated, and purified using a flash column chromatography system (dichloromethane: methanol 20: 1 to 5: 1) to obtain compound N12A12C4O2(1.03g, 96%).1H NMR(400MHz,DMSO-d6)：δ4.15(m,2H)；3.94(m,1H)；3.18(m,2H)；2.90(m,1H),2.73(m,1H),2.62(m,1H),2.34(t,2H),2.16(s,6H),1.67(m,2H),1.39-1.18(m,40H),0.89(m,6H).ESI-MS calculated for C33H65N2O3 +[M+H]+537.5,found 537.7
Example 6: synthesis of Compound N16A10C5O10
1-hexadecyl-2-nonyl-6-oxypiperidine-3-carboxylic acid (988mg,2mmol), N-hydroxyethylpiperidine (387mg,3mol), and 50mL of methylene chloride were sequentially charged into a 250mL reaction flask, and after stirring and dissolution, dicyclohexylcarbodiimide (824mg,4mmol), 4-dimethylaminopyridine (5mg,0.04mmol) were further added and reacted at room temperature for 2 hours, washed with water for 3 times, dried over anhydrous sodium sulfate, and after concentration, purified using a flash column chromatography system (methylene chloride: methanol 20: 1 to 5: 1) to obtain the compound N16A10C5O10(1.03g, 96%).1H NMR(400MHz,DMSO-d6)：δ4.15(m,2H)；3.94(m,1H)；3.18(m,2H)；2.90(m,1H),2.73(m,1H),2.62(m,1H),2.34(t,2H),2.16(s,6H),1.67(m,2H),1.39-1.18(m,40H),0.89(m,6H).ESI-MS calculated for C33H65N2O3 +[M+H]+606.0,found 606.3
Example 7: synthesis of Compound N12A12C4D1
1-dodecyl-5-oxo-2-undecylpyrrolidine-3-carboxylic acid (903mg,2mmol), N, N-dimethylethylenediamine (353mg,4mol), and 50mL of dichloromethane were sequentially added to a 250mL reaction flask, and after stirring and dissolving, O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate (HATU,1.14g,3mmol), and N, N-diisopropylethylamine (516mg,4mmol) were added, and after reaction at room temperature for 2 hours, after completion of TLC detection reaction, dichloromethane 200mL was added, washing was performed 3 times, drying was performed using anhydrous sodium sulfate, concentration was performed, and purification was performed using a flash column chromatography system (dichloromethane: methanol ═ 20: 1 to 5: 1) to obtain compound N12A12C4D1(982mg, 94%).1H NMR(400MHz,DMSO-d6)：δ4.17(m,2H)；3.95(m,1H)；3.19(m,2H)；2.91(m,1H),2.72(m,1H),2.63(m,1H),2.34(t,2H),2.16(s,6H),1.67(m,2H),1.39-1.18(m,38H),0.89(m,6H).ESI-MS calculated for C32H64N3O2 +[M+H]+522.5,found 522.9
Example 8: synthesis of Compound N12A20C4O10
1-dodecyl-5-oxo-2-undecylpyrrolidine-3-carboxylic acid (903mg,2mmol), N-hydroxyethylpiperidine (387mg,3mol), and 50mL of dichloromethane were sequentially added to a 250mL reaction flask, and after stirring and dissolving, dicyclohexylcarbodiimide (824mg,4mmol), 4-dimethylaminopyridine (5mg,0.04mmol) were added, and the mixture was reacted at room temperature for 2 hours, washed with water for 3 times, dried over anhydrous sodium sulfate, concentrated, and purified using a flash column chromatography system (dichloromethane: methanol: 20: 1 to 5: 1) to obtain N12A20C4O10(1.03g, 96%).1H NMR(400MHz,DMSO-d6)：δ4.15(m,2H)；3.94(m,1H)；3.18(m,2H)；2.90(m,1H),2.73(m,1H),2.62(m,1H),2.34(t,2H),2.16(s,6H),1.67(m,2H),1.39-1.18(m,40H),0.89(m,6H).ESI-MS calculated for C33H65N2O3 +[M+H]+644.1,found 644.3
Example 9: evaluation of luciferase mRNA in vivo delivery Performance of lipid nanoparticles prepared from amino lipid Compound
The preparation method comprises the following steps: the mol ratio of the amino lipidic compound to DSPC, cholesterol and PEG2000-DMG is 50: 10: 38.5: 1.5 in absolute ethanol. Luciferase mrna (fluc mrna) was dissolved in sodium acetate solution (50mM, pH 4.0). Two micro-syringe pumps were used, the ratio of ethanol solution to sodium acetate solution (50mM, pH 4.0) was controlled to 1: 3, preparing a crude solution of lipid nanoparticles in a micro-flow channel chip, dialyzing with a dialysis cartridge (Fisher, MWCO 20,000) at 1 XPBS and a controlled temperature of 4 ℃ for 6h, and filtering with a 0.22 μm microporous membrane before use. The mass ratio of aminolipid compound to luciferase mrna (fluc mrna) was about 10: 1.
animal preparation: selecting male BALB/c mice of 6 weeks old, weighing about 20g, and feeding in SPF-level feeding room, wherein animal experiments are strictly carried out according to the guidelines of the national health institution and the ethical requirements of animals.
In vivo delivery: 3 mice per group were randomly selected and intramuscular injected with lipid nanoparticles at a dose of 0.5 mg/kg. After 6 hours, 200. mu.L of 10mg/mL D-fluorescein potassium salt was injected into each mouse via the tail vein, and after 10 minutes, the mice were placed under an in vivo imaging system (IVIS-200, Xenogen), and the total fluorescence intensity of each mouse was observed and recorded by photographing. Table 1 shows that intramuscular administration of representative amino lipid compounds delivered the expression intensity of Fluc mRNA, and DLin-MC3 was used as a control, and a number of the amino lipids were similar to the expression intensity of MC3 and were significantly better than the positive control.
TABLE 1
Example 10: in vivo delivery of ovalbumin mRNA and evaluation of immunological properties of lipid nanoparticles prepared from amino lipid compounds
The preparation method comprises the following steps: the mol ratio of the amino lipidic compound to DSPC, cholesterol and PEG2000-DMG is 50: 10: 38.5: 1.5 in absolute ethanol. Ovalbumin mrna (ova mrna) was dissolved in sodium acetate solution (50mM, pH 4.0). Two micro-syringe pumps were used, the ratio of ethanol solution to sodium acetate solution (50mM, pH 4.0) was controlled to 1: 3, preparing a crude solution of lipid nanoparticles in a micro-flow channel chip, dialyzing with a dialysis cartridge (Fisher, MWCO 20,000) at 1 XPBS and a controlled temperature of 4 ℃ for 6h, and filtering with a 0.22 μm microporous membrane before use. The mass ratio of aminolipid compound to ovalbumin mrna (ova mrna) was about 10: 1.
animal preparation: selecting male BALB/c mice of 6 weeks old, weighing about 20g, and feeding in SPF-grade feeding room, wherein animal experiments are strictly carried out according to the guidelines of the national health institution and the requirements of animal ethics.
In vivo delivery: 3 mice were randomly selected per group and injected subcutaneously with lipid nanoparticles (Day 0) at a dose of 0.5 mg/kg. After 7 days, the same amount was used for another boost (Day 7). Tail vein bleeds were taken on day 21 for serological analysis.
Enzyme linked immunosorbent assay (ELISA): flat bottom 96 well plates (Nunc) were pre-coated in 50mM carbonate buffer at a concentration of 0.5 μ g protein per well (pH 9.6) overnight at 4 ℃, then blocked with 5% glycine, antiserum obtained from immunized animals were diluted from 102 to 106 PBS-0.05% Tween (PBS-T), pH 7.4, and added to wells and incubated at room temperature for 1 hour at 37 ℃, horseradish peroxidase (HRP) conjugated goat anti-mouse IgG in PBS-T-1% BSA at 1: a dilution of 10,000 was labeled. After addition of the HRP substrate, absorbance at 450nm was measured in an optical density ELISA plate reader (Bio-Rad) at one wavelength. As shown in fig. 1, N12a12C4O2 was comparable to the IgG antibody titration generated by MC3, while the IgG antibody titration of N16a10C5O10, N12a12C4D1, N12a20C4O10 was significantly better than the MC3 control.
Thus, the amino lipid compound can be placed in an aqueous solution to produce nano-sized materials, i.e., lipid nanoparticles, i.e., liposomes used to encapsulate drugs in lipid bilayers or in the internal aqueous space of liposomes, where liposomes are vesicles composed of bilayers of amphiphilic molecules that encapsulate the aqueous compartments, such as lipid bilayers vesicles (liposomes), multilamellar vesicles, or micelles, where the lipid is placed in water to first form lipid vesicles and then a bilayer or series of bilayers, each separated by water molecules, can be formed by lipid vesicles in water by ultrasound, where the lipid bilayer is a thin film formed by two layers of lipid molecules, where micelles are aggregates of surfactant molecules dispersed in liquid colloids, where typical micelles in aqueous solutions form aggregates with the hydrophilic head regions when exposed to water, a hydrophobic single tail region in the center of the chelating micelle; lipid particles formed from lipid compounds in gene therapy introduce foreign genes into target cells to correct or compensate for diseases caused by defective and abnormal genes for therapeutic purposes, such as treatment of cancer and genetic diseases; the cancer is one or more of lung cancer, gastric cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymph cancer, blood cancer or prostate cancer, and the genetic disease is one or more of hemophilia, thalassemia and gaucher's disease; in vaccination, amino-lipid compounds are used to deliver antigens or nucleic acids encoding antigens that elicit immune responses against various antigens that are used to treat and/or prevent a variety of conditions, such as cancer, allergy, toxicity, and infection by pathogens (e.g., viruses, bacteria, fungi, and other pathogenic organisms); the nucleic acid in the nucleic acid transfer is any one of RNA, mRNA (messenger RNA), antisense oligonucleotide, DNA, plasmid, rRNA (ribosomal RNA), miRNA (microrna), tRNA (transfer RNA), siRNA (small inhibitory RNA), snRNA (small nuclear RNA), and can be used in gene therapy, gene vaccination, antisense therapy, or therapy by interfering RNA in a patient. The nucleic acid has a biological effect when introduced into a cell or host as a biologically active agent, for example, by stimulating an immune or inflammatory response, by exerting an enzymatic activity or by supplementing mutations or the like, the biologically active agent being in particular a nucleic acid, a peptide, a protein, an antibody and a small molecule, or a member selected from the group consisting of antineoplastic agents, antibiotics, immunomodulators, anti-inflammatory agents, agents acting on the central nervous system, polypeptides or polypeptides (polypeptoids); of course, the bioactive agent can also be an anti-tumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or fragment thereof, a protein, a peptide, a polypeptide, a vaccine, a small molecule, or a mixture thereof; furthermore, one or more of a helper lipid, a sterol, a polyethylene glycol lipid may be added to the application of the amino-lipidic compound, such as the helper lipid being a non-cationic lipid, the sterol being cholesterol, the polyethylene glycol lipid being PEG2000-DMG ((1- (monomethoxypolyethylene glycol) -2,3 dimyristoyl glycerol), the non-cationic lipid may contain cationic functional groups (e.g., ammonium groups) but should contain anionic functional groups to at least neutralize the molecule, the totality of all functional groups in the lipid molecule should be non-cationic, liposomes consisting of a mixture of cationic amino lipids and non-cationic (neutral) phospholipids being most effective in delivering nucleic acids into cells, e.g., the non-cationic lipid is DOPE (dioleoylphosphatidylethanolamine) or DSPC (distearoylphosphatidylcholine), is a natural component in cell membranes that can be used to stabilize particles and aid in integration with cell membranes; polyethylene glycol lipids (PEG lipids) help protect the particles and their contents from degradation in vitro or in vivo, PEG forms a protective layer on the liposome surface and increases circulation time in vivo, and can be used in liposomal drug delivery (PEG-liposomes) which can be used to transfect multicellular tissues or organs, providing a novel therapeutic treatment to patients, which can be any mammal, preferably from humans, mice, rats, pigs, cats, dogs, horses, goats, cattle and monkeys, and/or others.
It will be understood that modifications and variations can be made by persons skilled in the art in light of the above teachings and all such modifications and variations are intended to be included within the scope of the invention as defined in the appended claims.
Claims (8)
1. An amino lipidic compound, characterized in that: a compound of formula I, or a stereoisomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof:
wherein:
R1-R2independently of each other, selected from the following structures: the R is1Is selected from the following N6, N7, N8,One of N9, N10, N11, N12, N13, N14, N15, N16, N18, N19, N20:
N6:CH3(CH2)5-；N7:CH3(CH2)6-；N8:CH3(CH2)7-；
N9:CH3(CH2)8-；N10：CH3(CH2)9-；N11:CH3(CH2)10-；
N12:CH3(CH2)11-；N13:CH3(CH2)12-；N14:CH3(CH2)13-；
N15:CH3(CH2)14-；N16:CH3(CH2)15-；N18:CH3(CH2)17-；
N19:
N20:
the R is2Is one selected from a6, a7, A8, a9, a10, a11, a12, a13, a14, a15, a16, a18, a19, a 20:
A6:CH3(CH2)4-；A7:CH3(CH2)5-；A8:CH3(CH2)6-；
A9:CH3(CH2)7-；A10：CH3(CH2)8-；A11:CH3(CH2)9-；
A12:CH3(CH2)10-；A13:CH3(CH2)11-；A14：CH3(CH2)12-；
A15:CH3(CH2)13-；A16:CH3(CH2)14-；A18:CH3(CH2)16-；
A19:
A20:
-X-L-N(R3)(R4) Is any one of O1, O2, O3, O4, O5, O6, O7, O8, O9, O10, D1, D2, D3, D4, D5, D6, D7, D8, D9, D10 selected from the following:
O1：
O2：
O3：
O4：
O5：
O6：
O7：
O8：
O9：
O10：
D1：
D2：
D3：
D4：
D5：
D6：
D7：
D8：
D9：
D10：
n is 1 or 2.
2. The amino lipidic compound of claim 1, wherein said amino lipidic compound is selected from the group consisting of:
3. a method for preparing an amino lipid compound, comprising: the method comprises the following steps:
s1, reacting compound NH2-R1And R2-CHO is stirred in solvent for reaction, then cyclic acid anhydride is added after the solvent is removed by distillation, the compound (II) is obtained after temperature rise reaction and purification, the structural formula is as follows,
s2, reacting the compound (II) with
The alcohol or amine is reacted in the presence of a condensing agent to prepare the compound (I), the structural formula is as follows,
wherein:
R1-R2independently of each other, selected from the following structures: the R is1Is one of N6, N12, N13, N16, N19, N20 selected from:
N6:CH3(CH2)5-；N12:CH3(CH2)11-；N13:CH3(CH2)12-；N16:CH3(CH2)15-；
N19:
N20:
the R is2Is one selected from a9, a10, a12, a13, a16, a18, a19, a 20:
A9:CH3(CH2)7-；A10：CH3(CH2)8-；A12:CH3(CH2)10-；A13:CH3(CH2)11-；A16:CH3(CH2)14-；A18:CH3(CH2)16-；
A19:
A20:
-X-L-N(R3)(R4) Is any one selected from the group consisting of O2, O5, O6, O8, O9, O10, D1, D4, D5, and D6:
O2：
O5：
O6：
O8：
O9：
O10：
D1：
D4：
D5：
D6：
n is 1 or 2.
4. Use of the aminolipidated compound of claims 1-2 in the manufacture of a medicament for gene therapy, gene vaccination, antisense therapy, interfering RNA or nucleic acid transfer, wherein when n ═ 1, X is not O in the manufacture of a medicament for nucleic acid transfer.
5. Use of an aminolipid compound according to claim 4, characterized in that: the nucleic acid is RNA or DNA.
6. Use of an aminolipid compound according to claim 4, characterized in that: the nucleic acid is an antisense oligonucleotide.
7. Use of the amino lipid compound according to claim 5, characterized in that: the RNA is any one of mRNA, rRNA, miRNA, tRNA, siRNA and snRNA.
8. Use of an amino lipid compound according to claim 5, characterized in that: the DNA is a plasmid.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110178738.7A CN112961091B (en) | 2021-02-07 | 2021-02-07 | Amino lipide compound and preparation method and application thereof |
| US18/264,397 US20240124396A1 (en) | 2021-02-07 | 2022-01-27 | Amino lipid compound, preparation method therefor, and use thereof |
| PCT/CN2022/074272 WO2022166747A1 (en) | 2021-02-07 | 2022-01-27 | Amino lipid compound, preparation method therefor, and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110178738.7A CN112961091B (en) | 2021-02-07 | 2021-02-07 | Amino lipide compound and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112961091A CN112961091A (en) | 2021-06-15 |
| CN112961091B true CN112961091B (en) | 2022-06-17 |
Family
ID=76284554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110178738.7A Active CN112961091B (en) | 2021-02-07 | 2021-02-07 | Amino lipide compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112961091B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240124396A1 (en) * | 2021-02-07 | 2024-04-18 | Shenzhen Shenxin Biotechnology Co., Ltd. | Amino lipid compound, preparation method therefor, and use thereof |
| CN115925604A (en) * | 2021-09-22 | 2023-04-07 | 广州谷森制药有限公司 | Pyrrolidine novel lipid compound, preparation method, composition and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011154457A1 (en) * | 2010-06-09 | 2011-12-15 | L'oreal | 2-pyrrolidone derivatives functionalized with an ester, acid or amide radical, cosmetic composition comprising them and use thereof for conditioning keratin materials |
| WO2011154458A1 (en) * | 2010-06-09 | 2011-12-15 | L'oreal | Composition comprising at least one 2-pyrrolidone functionalized with an ester or amide radical, and at least one pigment or direct dye, for dyeing keratin materials |
| WO2015125892A1 (en) * | 2014-02-19 | 2015-08-27 | 国立大学法人京都大学 | Protein labeling compound |
| CN106795096A (en) * | 2014-06-25 | 2017-05-31 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle preparation for delivering nucleic acid |
| CN108368028A (en) * | 2015-10-28 | 2018-08-03 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle preparation for delivering nucleic acid |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120744B2 (en) * | 2007-04-16 | 2015-09-01 | The Regents Of The University Of Michigan | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US10968176B2 (en) * | 2014-09-14 | 2021-04-06 | Nanosynthons Llc | Pyrrolidone derivatives, oligomers and polymers |
-
2021
- 2021-02-07 CN CN202110178738.7A patent/CN112961091B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011154457A1 (en) * | 2010-06-09 | 2011-12-15 | L'oreal | 2-pyrrolidone derivatives functionalized with an ester, acid or amide radical, cosmetic composition comprising them and use thereof for conditioning keratin materials |
| WO2011154458A1 (en) * | 2010-06-09 | 2011-12-15 | L'oreal | Composition comprising at least one 2-pyrrolidone functionalized with an ester or amide radical, and at least one pigment or direct dye, for dyeing keratin materials |
| WO2015125892A1 (en) * | 2014-02-19 | 2015-08-27 | 国立大学法人京都大学 | Protein labeling compound |
| CN106795096A (en) * | 2014-06-25 | 2017-05-31 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle preparation for delivering nucleic acid |
| CN108368028A (en) * | 2015-10-28 | 2018-08-03 | 爱康泰生治疗公司 | Novel lipid and lipid nanoparticle preparation for delivering nucleic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112961091A (en) | 2021-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8192753B2 (en) | pH-sensitive cationic lipids, and liposomes and nanocapsules containing the same | |
| CN112891560B (en) | mRNA delivery carrier and preparation method and application thereof | |
| CN114073677B (en) | Lipid nanoparticle | |
| US20060084617A1 (en) | Methods for delivery of nucleic acids | |
| CN112961091B (en) | Amino lipide compound and preparation method and application thereof | |
| CN107406396B (en) | Cationic lipid | |
| US20230149562A1 (en) | Carriers for efficient nucleic acid delivery | |
| WO2023029928A1 (en) | Amino lipid and application thereof | |
| WO2023236976A1 (en) | Lipid compound and preparation method therefor, and use thereof | |
| JP7411824B2 (en) | Aminolipid compounds, their preparation methods, and their uses | |
| CN116574070A (en) | Multi-tail type ionizable lipid, and preparation method and application thereof | |
| WO2022166747A1 (en) | Amino lipid compound, preparation method therefor, and use thereof | |
| CA3214023A1 (en) | Dendritic architectures as nonviral vectors in gene delivery | |
| WO2021193397A1 (en) | Novel cationic lipid having cystine skeleton | |
| CN113968968A (en) | Amino lipid compound, preparation method and application thereof | |
| CN113403313B (en) | sgRNA, plasmid and nano-composite for specifically recognizing human PLK1 locus and application | |
| CN117915958A (en) | Dendritic structures as non-viral vectors in gene delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518000 floor 6, block B, Tsinghua information port, No. 1, songpingshan Xindong Road, songpingshan community, Xili street, Nanshan District, Shenzhen, Guangdong Applicant after: Shenzhen Xinxin Biotechnology Co.,Ltd. Address before: 518000 b515, building 7, Shenzhen Bay science and technology ecological park, 1819 Shahe West Road, high tech community, Yuehai street, Nanshan District, Shenzhen City, Guangdong Province Applicant before: Shenzhen Xinxin Biotechnology Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |